NDA 020630 · Mylan Institutional
Ultiva
Remifentanil Hydrochloride · Injection
NovelLast checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Jul 12, 1996
Approved uses
4
Original approval plus efficacy supplements
Registered trials
814
54 Phase 3, 47 recruiting
FAERS reports
2,419
2,326 serious, 247 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ULTIVA Addiction, Abuse, and Misuse Because the use of ULTIVA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of ULTIVA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ULTIVA are essential [see Warnings and Precautions (5.2) ] . Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous...
What it is approved for
From the label in effect Dec 15, 2025.
ULTIVA is indicated for intravenous (IV) administration: • As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. • For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. • As an analgesic component of monitored anesthesia care in adult patients. ULTIVA is an opioid agonist indicated for intravenous administration: • As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. ( 1 ) • For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. ( 1 ) • As an analgesic component of monitored anesthesia care in adult patients. ( 1 )
Mechanism: ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of ULTIVA is antagonized by opioid antagonists, including overdose reversal agents such as naloxone or nalmefene. Unlike other opioids, ULTIVA is rapidly metabolized by hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases. ULTIVA is not a substrate for plasma cholinesterase (pseudocholinesterase) and, therefore, patients with atypical cholinesterase are expected to have a normal duration of action.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 8, 2004 Supplement 5 · Efficacy LabelLetter
- Nov 23, 1999 Supplement 2 · Efficacy
- Oct 15, 1999 Supplement 1 · Efficacy
- Jul 12, 1996 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
- ULTIVA · REMIFENTANIL HYDROCHLORIDE EQ 5MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- ULTIVA · REMIFENTANIL HYDROCHLORIDE EQ 1MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- ULTIVA · REMIFENTANIL HYDROCHLORIDE EQ 2MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Remifentanil" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal IntubationPivotal-lookingRecruiting
Nordsjaellands HospitalAcademic, hospital or other
NCT06564857 · 2,684 participants (planned) · Start Nov 17, 2025 · Primary completion Apr 1, 2027
Drug: Remifentanil; Rocuronium · For: Tracheal Intubation; Video Laryngoscopy; Remifentanil and 1 more
Sites: Copenhagen, Denmark; Hillerød, Denmark
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
- the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short OperationPivotal-lookingStatus unknown
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT02635802 · 1,500 participants (planned) · Start Dec 2015 · Primary completion Jun 2016
Drug: Remifentanil; Lidocaine and 2 more · For: Critical Illness
- Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal SurgeryPivotal-lookingStatus unknown
Second Affiliated Hospital of Nanchang UniversityAcademic, hospital or other
NCT05624424 · 1,317 participants (planned) · Start Nov 15, 2022 · Primary completion Oct 31, 2023
Drug: Rematazolam Besylate; Propofol and 4 more · For: Emergence Agitation; Remimazolam Besylate; Perioperative Sedation and 2 more
Sites: Ganzhou, China; Jiujiang, China; Nanchang, China · 6 sites in all
- Impact of Anesthesia Maintenance Methods on Incidence of Postoperative DeliriumPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT02662257 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 29, 2017
Drug: Sevoflurane; Propofol · For: Delirium; Postoperative Complications; Postoperative Cognitive Dysfunction
Sites: Beijing, China; Nanning, China; Shenzhen, China · 17 sites in all
- Impact of Anesthesia Maintenance Methods on 5-year Survival After SurgeryPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT05343260 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 30, 2022
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Guiyang, China · 15 sites in all
- Impact of Anesthesia Maintenance Methods on Long-term SurvivalPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT02660411 · 1,228 participants · Start Apr 1, 2015 · Primary completion Sep 29, 2017
Drug: Sevoflurane; Propofol · For: Aged; Neoplasms; Surgical Procedure, Operative and 3 more
Sites: Beijing, China; Nanning, China; Shenzhen, China · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaphylactic shock370
- hypotension166
- anaphylactic reaction151
- cardiac arrest122
- blood pressure decreased105
- bradycardia88
- tachycardia87
- bronchospasm78
- rash72
- erythema63
- toxic epidermal necrolysis62
- drug ineffective59
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 26 |
| 2005 | 41 |
| 2006 | 24 |
| 2007 | 43 |
| 2008 | 67 |
| 2009 | 80 |
| 2010 | 104 |
| 2011 | 90 |
| 2012 | 128 |
| 2013 | 166 |
| 2014 | 129 |
| 2015 | 109 |
| 2016 | 144 |
| 2017 | 95 |
| 2018 | 155 |
| 2019 | 125 |
| 2020 | 111 |
| 2021 | 98 |
| 2022 | 151 |
| 2023 | 149 |
| 2024 | 126 |
| 2025 | 131 |
| 2026 | 126 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01).
Current · updated Nov 18, 2026
Ultiva, Injection, 2 mg (NDC 72078-035-02).
Current · updated Nov 18, 2026
Ultiva, Injection, 5 mg (NDC 72078-036-05).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparison of Fentanyl, Remifentanil, Sufentanil and Alfentanil in Combination with Propofol for General Anesthesia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sridharan K, Sivaramakrishnan G · Curr Clin Pharmacol 2019 · Comparative Study, Meta-Analysis
- Remifentanil for External Cephalic Version: A Systematic Review and Meta-Analysis.
Koonce BT, Castillo JDD, Tubog TD, et al. · AANA J 2023 · Meta-Analysis, Systematic Review
- Severe cardiovascular depression with remifentanil.
Elliott P, O'Hare R, Bill KM, et al. · Anesth Analg 2000 · Clinical Trial, Randomized Controlled Trial
- Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.
Takekita Y, Suwa T, Sunada N, et al. · Eur Arch Psychiatry Clin Neurosci 2016 · Meta-Analysis, Systematic Review
- Dexmedetomidine versus remifentanil in nasal surgery: a systematic review and meta-analysis.
Janipour M, Bastaninejad S, Mohebbi A, et al. · BMC Anesthesiol 2024 · Systematic Review, Meta-Analysis
- Remifentanil pretreatment reduces myoclonus after etomidate.
Kelsaka E, Karakaya D, Sarihasan B, et al. · J Clin Anesth 2006 · Comparative Study, Randomized Controlled Trial
Sponsor: Mylan Institutional
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.